GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Revelation Biosciences Inc (FRA:56U0) » Definitions » Median PS Value

Revelation Biosciences (FRA:56U0) Median PS Value : €0.00 (As of May. 29, 2024)


View and export this data going back to 2022. Start your Free Trial

What is Revelation Biosciences Median PS Value?

This valuation method assumes that the stock valuation will revert to its historical (10-Year) mean in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.

Median PS Value is calculated as trailing twelve months (TTM) Revenue per Share times 10-Year median PS Ratio. Revelation Biosciences's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2024 was €0. Revelation Biosciences's 10-Year median PS Ratio is . Therefore, the Median PS Value for today is €0.00.

As of today (2024-05-29), Revelation Biosciences's share price is €8.88. Revelation Biosciences's Median PS Value is €0.00. Therefore, Revelation Biosciences's Price to Median PS Value for today is 0.00.

The historical rank and industry rank for Revelation Biosciences's Median PS Value or its related term are showing as below:

FRA:56U0's Price-to-Median-PS-Value is not ranked *
in the Biotechnology industry.
Industry Median: 0.68
* Ranked among companies with meaningful Price-to-Median-PS-Value only.

Revelation Biosciences Median PS Value Historical Data

The historical data trend for Revelation Biosciences's Median PS Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Revelation Biosciences Median PS Value Chart

Revelation Biosciences Annual Data
Trend Dec20 Dec21 Dec22 Dec23
Median PS Value
- - - -

Revelation Biosciences Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Median PS Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Revelation Biosciences's Median PS Value

For the Biotechnology subindustry, Revelation Biosciences's Price-to-Median-PS-Value, along with its competitors' market caps and Price-to-Median-PS-Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Revelation Biosciences's Price-to-Median-PS-Value Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Revelation Biosciences's Price-to-Median-PS-Value distribution charts can be found below:

* The bar in red indicates where Revelation Biosciences's Price-to-Median-PS-Value falls into.



Revelation Biosciences Median PS Value Calculation

Revelation Biosciences's Median PS Value for today is calculated as

Median PS Value=Revenue per Share (TTM)*10-Year Median PS Ratio
=0*
=0.00

10-Year Median PS Ratio is .
Revelation Biosciences's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Revelation Biosciences  (FRA:56U0) Median PS Value Explanation

This valuation method assumes that the stock valuation will revert to its historical (10-Year) mean in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.

It also assumes that over time the profit margin is constant. If a company increases its profit margin to a sustainable level, this value might under-estimate its value. If it has permanent declined profit margins, this may over-estimate the company's value.

Revelation Biosciences's Price to Median PS Value for today is calculated as

Price to Median PS Value=Share Price/Median PS Value
=8.88/0.00
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Revelation Biosciences Median PS Value Related Terms

Thank you for viewing the detailed overview of Revelation Biosciences's Median PS Value provided by GuruFocus.com. Please click on the following links to see related term pages.


Revelation Biosciences (FRA:56U0) Business Description

Traded in Other Exchanges
Address
4660 La Jolla Village Drive, Suite 100, San Diego, CA, USA, 92122
Revelation Biosciences Inc is a clinical-stage life sciences company focused on the development of immunologic-based therapies for the prevention and treatment of disease. It has several product candidates in development. REVTx-99, the lead therapeutic candidate, is an intranasal immunomodulator to prevent or treat infections caused by various respiratory viruses such as SARS-CoV-2, including its variants, influenza A and B, parainfluenza, rhinovirus, and RSV. REVTx-99 is also being developed for other indications such as: allergic rhinitis and chronic nasal congestion. REVTx-200 is an intranasal immunomodulator adjunct to be used in combination with an intramuscular vaccination for more complete immunity. REVTx-200 is based on the same technology used in REVTx-99.

Revelation Biosciences (FRA:56U0) Headlines

No Headlines